GlaxoSmithKline faces a shareholder revolt over its dismal share price performance, The Observer reported, citing institutional investors and analysts.
The newspaper said anger has spilt into discussions between investors and chairman Sir Christopher Gent over who should succeed chief executive Jean-Pierre Garnier, who is due to retire in May 2008.
GSK's big institutional shareholders have held meetings with Gent and told him in no uncertain terms that Garnier's successor should be someone who is prepared to undertake a fundamental overhaul of the company and consider a radical streamlining of its operations, including a possible break-up, the newspaper said.
Source
No comments:
Post a Comment